Larimar Therapeutics, Inc. filings document a clinical-stage biotechnology issuer developing nomlabofusp for Friedreich’s ataxia and other potential rare-disease programs using an intracellular delivery platform. Its 8-K reports disclose operating and financial results, FDA-related program updates, corporate presentations, material events and risk language around product development, regulatory review, capital needs and clinical execution.
The company’s SEC record also includes capital-structure and governance disclosures. Filings describe registered common stock on the Nasdaq Global Market, equity financing activity, an exchange involving Series A convertible preferred stock, preferred-stock conversion limitations, shareholder voting matters, executive compensation and board governance through proxy materials.
Larimar Therapeutics, Inc. Chief Medical Officer Clayton Russell reported a direct purchase of 3,322 common shares on November 16, 2026, at $3.01 per share. He reported direct holdings of 74,765 shares after the purchase. No Rule 10b5-1 plan is reported, and the transaction is described as a purchase in the open market or a private transaction.
Larimar Therapeutics, Inc. (LRMR) director Jeffrey W. Sherman purchased 3,289 shares of common stock on November 16, 2026, at $3.0576 per share. His directly held position following the purchase was 8,289 shares. The transaction was not made under a Rule 10b5-1 trading plan. It is described as a purchase in the open market or a private transaction.
Larimar Therapeutics, Inc. (LRMR) completed its rolling Biologics License Application submission to the FDA in November 2026, seeking accelerated approval of nomlabofusp based on increased tissue frataxin concentrations as a potential novel surrogate endpoint. It requested priority review and issuance of a rare pediatric disease priority review voucher at approval. Patients are enrolling in the global Phase 3 FORWARD-FA study. June 2026 open-label data showed skin FXN above asymptomatic-carrier levels in 82% (9/11) of participants at six months and 100% (9/9) at one year. Ten participants experienced anaphylaxis and discontinued; all responded to standard therapy and returned to their usual health with no further sequelae.
Third-quarter net loss was $31.1 million, versus $47.7 million a year earlier; nine-month net loss was $93.5 million, versus $103.2 million. Nine-month net cash used in operating activities was $119.8 million, compared with $74.7 million. At September 30, 2026, Larimar had approximately $128.7 million in cash, cash equivalents and marketable securities, which it expected to fund forecast expenses into late Q2 2027. The company said those resources were insufficient for at least one year after the statements were issued, raising substantial doubt about its ability to continue as a going concern, and that it will need additional capital.
Larimar Therapeutics, Inc. (LRMR) is the issuer in a Schedule 13G in which RTW Investments, LP and its managing partner and chief investment officer, Roderick Wong, M.D., each reported beneficial ownership of the same 5,820,891 common shares, or 5.6%, on September 30, 2026. The shares are held directly by the RTW Funds; both reporting persons reported shared voting and dispositive power and zero sole voting and dispositive power. The RTW Funds have the right to receive dividends or direct receipt of proceeds from sales of the shares. The reporting persons state that the filing is not an admission of beneficial ownership under Section 13 of the Exchange Act.
Larimar Therapeutics, Inc. (LRMR) completed its rolling BLA submission seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, using FXN as a potential novel surrogate endpoint. The company said FDA indicated the existing data package appeared capable of supporting submission and review and was willing to consider FXN; approval is subject to FDA review. Patients are enrolling in the confirmatory Phase 3 FORWARD-FA study.
As of September 30, 2026, Larimar had $128.7 million in cash, cash equivalents and marketable securities and projected cash runway into late Q2 2027. Q3 net loss was $31.1 million, compared with $47.7 million in Q3 2025; nine-month net loss was $93.5 million versus $103.2 million. Q3 research and development expense was $25.9 million versus $44.9 million, while general and administrative expense was $6.5 million versus $4.6 million.
The R&D decrease primarily reflected lower drug-manufacturing activity at third-party manufacturers; higher G&A primarily related to accelerated commercial preparations. Larimar targets a U.S. launch in Q3 2027 if nomlabofusp is approved.
Larimar Therapeutics, Inc. director Thomas Edward Hamilton reported that Cure FA Foundation, Inc. purchased 70,000 common shares on November 12, 2026, at a weighted average price of $2.6726 per share. No Rule 10b5-1 plan is reported.
Hamilton reported holding 714,798 shares directly and 159,433 shares indirectly through Post Edison, LLC.
Larimar Therapeutics, Inc. (LRMR) President and CEO Carole Ben-Maimon purchased 18,050 shares on November 11, 2026, at a reported weighted-average price of $2.7675 per share; the purchases occurred in multiple transactions priced from $2.765 to $2.77, inclusive. Each share is represented by a restricted stock unit, a contingent right to receive one common share upon settlement. Her reported direct holdings after the purchase were 386,326 shares.
Larimar Therapeutics, Inc. (LRMR) director Frank E. Thomas purchased 8,000 shares of common stock on November 11, 2026, at $2.7250 per share. His directly held position following the purchase was 15,000 shares. No Rule 10b5-1 plan is reported for the purchase.
Larimar Therapeutics, Inc. director Joseph Truitt purchased 3,500 shares of common stock on November 11, 2026, at a weighted average price of $2.7976 per share. He directly held 6,250 shares after the purchase, and no Rule 10b5-1 plan is reported.
Larimar Therapeutics, Inc. President and COO John B. Harlow Jr. purchased 17,800 shares of common stock on November 11, 2026. The reported weighted average price was $2.8044 per share, across multiple transactions ranging from $2.7295 to $2.825 per share. He directly held 67,800 shares after the purchases. No Rule 10b5-1 plan is reported.